showed a trendp=0.057
In HPV-positive AJCC 8th edition N1 patients, those previously staged as N2b under AJCC 7th showed a trend toward inferior survival (74.5% vs. 86.2%, p=0.057).
In HPV-positive AJCC 8th edition N1 patients, those previously staged as N2b under AJCC 7th showed a trend toward inferior survival (74.5% vs. 86.2%, p=0.057).
Only a tendency towards significance in OS was observed in favor of the RT with 3-weekly cisplatin chemotherapy group.